Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041843 · ClinicalTrials.gov registry record · Phase 2
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
A Phase 2 study of Venous Thromboembolism, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04041843 is a Phase 2 study of Venous Thromboembolism that has completed, run by New York Medical College. The registered enrollment target is 25 participants, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04041843, a Phase 2 study of Venous Thromboembolism, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04041843
The ClinicalTrials.gov registry entry for NCT04041843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (100% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT04041843 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04041843 about?
NCT04041843 is a clinical study titled "Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism". Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
What is the current status of trial NCT04041843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-06-02. Estimated completion is 2022-05-31.
What conditions does trial NCT04041843 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT04041843?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT04041843?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04041843 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
RECRUITING · Phase 2
-
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
ACTIVE NOT RECRUITING · Phase 2
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.